EU Flag

Glycotope GmbH is project based co-funded by the European Fund for Regional Development [EFRE].
Biopharmaceuticals Pipeline Glycotope’s mature biopharmaceuticals pipeline Find out more
Biopharmaceuticals Services Glycotope’s unique development expertise Find out more

Using world-leading glycobiology expertise to improve outcomes for patients

About
An introduction to our company and experienced leadership
Technology
Learn how we are leveraging our proprietary technologies to drive innovation
Gatipotuzumab
Our first-in-class antibody against a tumor-specific carbohydrate-protein epitope
Careers
Join us
News
25. Mar
2019
Glycotope Expands Phase Ib Trial of Combination of Proprietary Anti-Tumor Antibodies to Include Marketed Anti-Tumor Antibodies

·         GATTO Study Extension to Evaluate Gatipotuzumab and Tomuzotuximab or         […]

30. Jul
2018
Daiichi Sankyo Enters Worldwide Licensing Agreement with Glycotope for Gatipotuzumab Antibody Drug Conjugate

Tokyo, Berlin, Basking Ridge, NJ – (July 30, 2018) – Daiichi Sankyo Company, Limited […]

See All News
Events
See All Events